Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

HE4 Serum Levels in Patients with BRCA1 Gene Mutation Undergoing Prophylactic Surgery as well as in Other Benign and Malignant Gynecological Diseases.

Disease markers - 1 Jan 2017

Chudecka-Głaz Anita, Cymbaluk-Płoska Aneta, Strojna Aleksandra, Menkiszak Janusz

Abstract excerpt

Objective. We assess the behavior of serum concentrations of HE4 marker in female carriers of BRCA1 and assess the diagnostic usefulness of HE4 in ovarian and endometrial cancer. Methods. A total of 619 women with BRCA1 gene mutation, ovarian, endometrial, metastatic, other gynecological cancers, or benign gynecological diseases were included. Intergroup comparative analyses were carried out, the BRCA1 gene...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adolescent
Share to Aged, 80 and over

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to BRCA1 Protein

Share to CA-125 Antigen

Share to Case-Control Studies

Share to Genital Neoplasms, Female

Share to Membrane Proteins

Share to Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 28182133
DOI: 10.1155/2017/9792756
PMCID: PMC5274692

Genes

BRCA1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

HE4 Serum Levels in Patients with BRCA1 Gene Mutation Undergoing Prophylactic Surgery as well as in Other Benign and Malignant Gynecological Diseases.PMID 28182133Read ↗

The effectiveness of CA125 and HE4 as clinical prognostic markers in epithelial ovarian cancer patients with BRCA mutation.Semantic proximity Read ↗

CT imaging phenotypes linked to CA125 and HE4 biomarkers are highly predictive in discriminating between hereditary and sporadic ovarian cancer patients.Semantic proximity Read ↗

HE4: a new potential early biomarker for the recurrence of ovarian cancerSemantic proximity Read ↗

Use of CA125 and HE4 serum markers to predict ovarian cancer in elevated-risk women.Semantic proximity Read ↗

Initial serum CA-125 and HE4 levels as predictors for optimal surgical cytoreduction in patients with stage III epithelial ovarian cancerSemantic proximity Read ↗

Human epididymis protein 4 and Lewis y enhance chemotherapeutic resistance in epithelial ovarian cancer through the p38MAPK pathwaySemantic proximity Read ↗

Beyond the Biomarker: Understanding the Diverse Roles of Human Epididymis Protein 4 in the Pathogenesis of Epithelial Ovarian CancerSemantic proximity Read ↗

HE4 (WFDC2) gene overexpression promotes ovarian tumor growthSemantic proximity Read ↗

Protein levels and gene expressions of the epidermal growth factor receptors, HER1, HER2, HER3 and HER4 in benign and malignant ovarian tumorsSemantic proximity Read ↗

Development of a longitudinal two-biomarker algorithm for early detection of ovarian cancer in women with BRCA mutations.Semantic proximity Read ↗

Reassessing HPSE in Ovarian Cancer: Beneficial After All?Semantic proximity Read ↗

The expression of BRCA1, P53, KAI1, and Nm23 in ovaries of BRCA1 mutation carriers after prophylactic adnexectomy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.